[go: up one dir, main page]

IN2015DN01480A - - Google Patents

Info

Publication number
IN2015DN01480A
IN2015DN01480A IN1480DEN2015A IN2015DN01480A IN 2015DN01480 A IN2015DN01480 A IN 2015DN01480A IN 1480DEN2015 A IN1480DEN2015 A IN 1480DEN2015A IN 2015DN01480 A IN2015DN01480 A IN 2015DN01480A
Authority
IN
India
Prior art keywords
compositions
methods
genetic disease
genetic
disease
Prior art date
Application number
Inventor
Gregory J Cost
Philip D Gregory
Dmitry Guschin
Michael C Holmes
Jeffrey C Miller
David Paschon
Edward J Rebar
Andreas Reik
Fyodor Urnov
Lei Zhang
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Publication of IN2015DN01480A publication Critical patent/IN2015DN01480A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Methods and compositions for a genetic disease are provided.
IN1480DEN2015 2012-08-29 2013-08-29 IN2015DN01480A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694693P 2012-08-29 2012-08-29
PCT/US2013/057214 WO2014036219A2 (en) 2012-08-29 2013-08-29 Methods and compositions for treatment of a genetic condition

Publications (1)

Publication Number Publication Date
IN2015DN01480A true IN2015DN01480A (en) 2015-07-03

Family

ID=50184630

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1480DEN2015 IN2015DN01480A (en) 2012-08-29 2013-08-29

Country Status (26)

Country Link
US (4) US9650648B2 (en)
EP (1) EP2890780B8 (en)
JP (4) JP2015533786A (en)
KR (3) KR102474010B1 (en)
CN (1) CN104704110B (en)
AU (1) AU2013308770B2 (en)
CA (2) CA2882499C (en)
CL (1) CL2015000450A1 (en)
DK (1) DK2890780T3 (en)
EA (1) EA039384B1 (en)
ES (1) ES2812599T3 (en)
HR (1) HRP20201443T1 (en)
HU (1) HUE050516T2 (en)
IL (1) IL237050B (en)
IN (1) IN2015DN01480A (en)
LT (1) LT2890780T (en)
MX (1) MX367081B (en)
PH (3) PH12021551661A1 (en)
PL (1) PL2890780T3 (en)
PT (1) PT2890780T (en)
RS (1) RS60838B1 (en)
SG (2) SG11201500852WA (en)
SI (1) SI2890780T1 (en)
UA (1) UA118957C2 (en)
WO (1) WO2014036219A2 (en)
ZA (1) ZA201500900B (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
NZ630900A (en) * 2012-02-24 2016-10-28 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
RS59199B1 (en) 2012-05-25 2019-10-31 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CN110066775B (en) * 2012-10-23 2024-03-19 基因工具股份有限公司 Compositions for cleaving target DNA and uses thereof
ES2757325T3 (en) 2012-12-06 2020-04-28 Sigma Aldrich Co Llc Modification and regulation of the genome based on CRISPR
CA2901676C (en) 2013-02-25 2023-08-22 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014197748A2 (en) * 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF GENOME EDITING WITH CRISPR / CAS SYSTEMS
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
EP3591045B1 (en) * 2013-08-28 2024-07-17 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2015070083A1 (en) 2013-11-07 2015-05-14 Editas Medicine,Inc. CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
SI3068881T1 (en) * 2013-11-13 2019-05-31 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
HRP20201038T1 (en) * 2014-02-03 2020-10-16 Sangamo Therapeutics, Inc. PROCEDURES AND PREPARATIONS FOR THE TREATMENT OF BETA THALASEMIA
JP6606088B2 (en) 2014-02-24 2019-11-13 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
EP3981876A1 (en) * 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
WO2015148860A1 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
EP3540061A1 (en) 2014-04-02 2019-09-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
GB2544001A (en) 2014-08-27 2017-05-03 Caribou Biosciences Inc Methods for increasing Cas9-mediated engineering efficiency
JP6722176B2 (en) * 2014-09-16 2020-07-15 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated genomic engineering and correction in hematopoietic stem cells
WO2016073955A2 (en) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
WO2016085934A1 (en) * 2014-11-24 2016-06-02 Children's Medical Center Corporation Modulation of sh2b3 to improve red blood cell production from stem cells and/or progenitor cells
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
CN107532168A (en) * 2015-02-23 2018-01-02 克里斯珀医疗股份公司 Materials and methods for the treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
EP3283653B1 (en) 2015-04-13 2021-06-30 Invitae Corporation Methods, systems and processes of identifying genetic variation in highly similar genes
SG11201708653RA (en) 2015-04-24 2017-11-29 Editas Medicine Inc Evaluation of cas9 molecule/guide rna molecule complexes
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
EP3294866A4 (en) 2015-05-12 2018-12-05 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
EP3325018B1 (en) * 2015-07-22 2025-01-15 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
ES3032775T3 (en) * 2015-09-23 2025-07-24 Sangamo Therapeutics Inc Htt repressors and uses thereof
CN108138155A (en) * 2015-10-20 2018-06-08 先锋国际良种公司 Restoring the function of a non-functional gene product via a guided CAS system and methods of use
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
KR102766526B1 (en) 2015-10-28 2025-02-13 상가모 테라퓨틱스, 인코포레이티드 Factor VIII expression cassette, a liver-specific construct, and methods of using the same
ES2942309T3 (en) 2015-11-04 2023-05-31 Vertex Pharma Materials and methods for the treatment of hemoglobinopathies
CN108699542A (en) 2015-11-13 2018-10-23 阿维利诺美国实验室股份有限公司 Method for treating corneal dystrophy
SG11201805157TA (en) 2015-12-18 2018-07-30 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
WO2017143071A1 (en) 2016-02-18 2017-08-24 The Regents Of The University Of California Methods and compositions for gene editing in stem cells
CN117802102A (en) * 2016-03-14 2024-04-02 爱迪塔斯医药公司 CRISPR/CAS related methods and compositions for treating beta-hemoglobinopathies
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
BR112019001887A2 (en) 2016-08-02 2019-07-09 Editas Medicine Inc compositions and methods for treating cep290-associated disease
EP3494215A1 (en) 2016-08-03 2019-06-12 President and Fellows of Harvard College Adenosine nucleobase editors and uses thereof
CN109804066A (en) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 Programmable CAS9- recombination enzyme fusion proteins and application thereof
WO2020225754A1 (en) 2019-05-06 2020-11-12 Mcmullen Tara Crispr gene editing for autosomal dominant diseases
KR102594051B1 (en) 2016-08-20 2023-10-26 아벨리노 랩 유에스에이, 인크. Single guide RNA, CRISPR/Cas9 system, and methods of use thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
BR112019003327A2 (en) 2016-08-24 2019-07-02 Sangamo Therapeutics, Inc. specific target engineered nucleases
DK3504229T3 (en) * 2016-08-24 2021-12-20 Sangamo Therapeutics Inc REGULATION OF GENEPRESSION USING MANIPULATED NUCLEASES
JP7256739B2 (en) 2016-09-07 2023-04-12 サンガモ セラピューティクス， インコーポレイテッド Modulation of liver genes
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018071663A1 (en) * 2016-10-14 2018-04-19 Emendobio Inc. Rna compositions for genome editing
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TWI758316B (en) * 2017-01-09 2022-03-21 美商聖加莫治療股份有限公司 Regulation of gene expression using engineered nucleases
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Composition and method for treating hemochromatosis
CN110662556A (en) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (en) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cytosine to Guanine Base Editing Agent
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US12110499B2 (en) 2017-04-24 2024-10-08 Seattle Children's Hospital Homology directed repair compositions for the treatment of hemoglobinopathies
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
MX2020000676A (en) 2017-07-18 2021-05-14 Csl Behring Gene Therapy Inc Compositions and methods for treating beta-hemoglobinopathies.
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
MA50849A (en) 2017-10-26 2020-09-02 Vertex Pharma SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
BR112020008568A2 (en) * 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. genetic modification of protein gene containing cytokine-inducible sh2 (cish)
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3511412A1 (en) * 2018-01-12 2019-07-17 Genethon Genetically engineered hematopoietic stem cell as a platform for systemic protein expression
MA51788A (en) 2018-02-05 2020-12-16 Vertex Pharma SUBSTANCES AND METHODS FOR TREATING HEMOGLOBINOPATHIES
KR20200118468A (en) * 2018-02-08 2020-10-15 상가모 테라퓨틱스, 인코포레이티드 Engineered target specific nuclease
US20190255284A1 (en) 2018-02-21 2019-08-22 Alcyone Lifesciences, Inc. Fluid Delivery Systems and Methods
KR20260006713A (en) 2018-03-14 2026-01-13 에디타스 메디신, 인코포레이티드 Systems and methods for the treatment of hemoglobinopathies
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CA3110345A1 (en) 2018-08-27 2020-03-05 Alcyone Lifesciences, Inc. Fluid delivery systems and methods
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
KR20210146986A (en) 2019-04-02 2021-12-06 상가모 테라퓨틱스, 인코포레이티드 Methods of treating beta-thalassemia
JP7469328B2 (en) * 2019-04-12 2024-04-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Correction of the beta-thalassemia phenotype by genetically engineered hematopoietic stem cells
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN112391410B (en) * 2020-02-17 2024-04-02 华东师范大学 sgRNA and application thereof in repairing abnormal splicing of introns
US20220280571A1 (en) * 2019-08-01 2022-09-08 The Regents Of The University Of California Compositions and methods for treating alpha thalassemia
EP4010004A4 (en) * 2019-08-07 2023-09-13 Altius Institute For Biomedical Sciences COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
CN114729376A (en) * 2019-09-23 2022-07-08 欧米茄治疗公司 Compositions and methods for modulating hepatocyte nuclear factor 4 alpha (HNF4 alpha) gene expression
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021076592A1 (en) * 2019-10-15 2021-04-22 Altius Institute For Biomedical Sciences Dna binding proteins for displacing endogenous transcription factors bound to gene regulatory regions
US20250263752A1 (en) 2020-04-21 2025-08-21 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
US20230165909A1 (en) 2020-04-21 2023-06-01 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
JP2023525304A (en) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
TW202342498A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae fusion glycoproteins
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
EP4473097A1 (en) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
CN121443743A (en) 2023-05-23 2026-01-30 赛纳生物技术公司 Tandem fusion agents and related lipid particles
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025153530A1 (en) 2024-01-16 2025-07-24 Novo Nordisk A/S Albumin-targeted endonucleases, compositions, and methods of use
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789538A (en) 1904-11-11 1905-05-09 Colin E Ham Dumb-bell.
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2181548C (en) 1994-01-18 2009-11-03 Carlos F. Barbas, Iii Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
WO1995025809A1 (en) 1994-03-23 1995-09-28 Ohio University Compacted nucleic acids and their delivery to cells
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
ATE466952T1 (en) 1998-03-02 2010-05-15 Massachusetts Inst Technology POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS
CO5070700A1 (en) 1998-06-05 2001-08-28 Basf Ag NOVELTY GENES OF (ADP-RIBOSA) POLYMERASE
US6140815A (en) 1998-06-17 2000-10-31 Dover Instrument Corporation High stability spin stand platform
US6532231B1 (en) 1998-08-29 2003-03-11 Lucent Technologies Inc. Arrangement for changing the destination of single link, single destination data messages
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
JP2002535995A (en) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション Gene repair involving induction of double-stranded DNA breaks at chromosomal target sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
DE60023936T2 (en) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS
KR20020086508A (en) 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 Cells for drug discovery
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (en) 2000-08-23 2002-02-26 Kao Corp Bactericidal antifouling agent for hard surfaces
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2002336373A1 (en) 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
BRPI0307383B1 (en) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation directed genetic recombination method in host plant cell
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
CA2497913C (en) 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005014791A2 (en) 2003-08-08 2005-02-17 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005232665B2 (en) 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
EP1737498A2 (en) 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zinc finger proteins for treatment of neuropathic pain
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
JP4988606B2 (en) 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド Anti-angiogenic methods and compositions
CA2607104A1 (en) 2005-05-05 2006-11-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
US20090263900A1 (en) 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
CA2615532C (en) * 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP2484758B1 (en) 2005-10-18 2013-10-02 Precision Biosciences Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
JP5266210B2 (en) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド Modified cleavage half-domain
ES2378333T3 (en) 2006-05-25 2012-04-11 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
CA2700231C (en) 2007-09-27 2018-09-18 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
BE1018531A4 (en) 2007-10-31 2011-03-01 Gielen Cornelis THE USE OF NON-PATHOGENIC BACTERIA IN TRACE FORM OR IN SLEEPING FOR REMOVAL OF HOUSEHOLDING EJECTS AND ORGANIC ALLERGY MATERIALS OF ALL TEXTILE TYPES.
DE102007056956B4 (en) 2007-11-27 2009-10-29 Moosbauer, Peter, Dipl.-Ing.(FH) Circuit for controlling the power supply of a consumer and method for operating a circuit
JP2011521643A (en) 2008-05-28 2011-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド Composition for linking a DNA binding domain and a cleavage domain
KR20160015400A (en) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 Methods and compositions for targeted single-stranded cleavage and targeted integration
ES2615829T3 (en) * 2008-09-15 2017-06-08 The Children's Medical Center Corporation Modulation of BCL11A for the treatment of hemoglobinopathies
JP5681114B2 (en) 2008-12-04 2015-03-04 サンガモ バイオサイエンシーズ， インコーポレイテッド Rat genome editing using zinc finger nuclease
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
KR20120038020A (en) 2009-08-11 2012-04-20 상가모 바이오사이언스 인코포레이티드 Organisms homozygous for targeted modification
DK2816112T3 (en) 2009-12-10 2018-11-19 Univ Minnesota TAL effector-mediated DNA modification
UA118328C2 (en) 2010-01-22 2019-01-10 Дау Агросайєнсіз Ллс Targeted gemomic alteration
PT2534173T (en) * 2010-02-08 2019-10-31 Sangamo Therapeutics Inc Engineered cleavage half-domains
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
LT2566972T (en) 2010-05-03 2020-03-10 Sangamo Therapeutics, Inc. Compositions for linking zinc finger modules
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US20140127814A1 (en) 2010-08-10 2014-05-08 Srinivasan Chandrasegaran Generation and use of pluripotent stem cells
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
WO2012073047A2 (en) 2010-12-03 2012-06-07 Genome Research Limited Compositions and methods
IL293650B2 (en) 2011-09-21 2024-10-01 Sangamo Therapeutics Inc Methods and preparations for regulating transgene expression
JP6188703B2 (en) 2011-10-27 2017-08-30 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for modifying the HPRT locus
NZ630900A (en) * 2012-02-24 2016-10-28 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
JP6559063B2 (en) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3730615A3 (en) * 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition

Also Published As

Publication number Publication date
SG10201701601WA (en) 2017-04-27
KR102218562B1 (en) 2021-02-19
IL237050A0 (en) 2015-03-31
ZA201500900B (en) 2017-09-27
ES2812599T3 (en) 2021-03-17
PH12015500433B1 (en) 2021-10-27
LT2890780T (en) 2020-11-10
AU2013308770A1 (en) 2015-03-05
MX2015002409A (en) 2015-10-05
US9963715B2 (en) 2018-05-08
JP6629917B2 (en) 2020-01-15
EP2890780B1 (en) 2020-06-24
JP2022001072A (en) 2022-01-06
PT2890780T (en) 2020-08-03
KR20150047498A (en) 2015-05-04
EA039384B1 (en) 2022-01-20
CN104704110A (en) 2015-06-10
HUE050516T2 (en) 2020-12-28
PL2890780T3 (en) 2021-02-08
HRP20201443T1 (en) 2020-12-11
US20180223311A1 (en) 2018-08-09
EP2890780A4 (en) 2016-08-31
JP2017217012A (en) 2017-12-14
CA3171494A1 (en) 2014-03-06
PH12015500433A1 (en) 2015-04-20
US11492643B2 (en) 2022-11-08
KR20220164090A (en) 2022-12-12
PH12019502292A1 (en) 2021-03-15
EP2890780A2 (en) 2015-07-08
SI2890780T1 (en) 2020-11-30
PH12021551661A1 (en) 2022-07-18
AU2013308770B2 (en) 2019-01-17
WO2014036219A2 (en) 2014-03-06
HK1210502A1 (en) 2016-04-22
US20230416775A1 (en) 2023-12-28
KR20210020174A (en) 2021-02-23
US9650648B2 (en) 2017-05-16
CN104704110B (en) 2018-06-01
MX367081B (en) 2019-08-05
CL2015000450A1 (en) 2015-07-10
CA2882499A1 (en) 2014-03-06
IL237050B (en) 2020-04-30
WO2014036219A3 (en) 2014-05-30
EP2890780B8 (en) 2020-08-19
JP2015533786A (en) 2015-11-26
DK2890780T3 (en) 2020-09-21
CA2882499C (en) 2023-09-26
UA118957C2 (en) 2019-04-10
US20140080216A1 (en) 2014-03-20
RS60838B1 (en) 2020-10-30
EA201590167A1 (en) 2015-11-30
KR102474010B1 (en) 2022-12-02
SG11201500852WA (en) 2015-04-29
US20140093913A1 (en) 2014-04-03
JP2018121661A (en) 2018-08-09
BR112015003815A2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
IN2015DN01480A (en)
IL230836A (en) Multi-part sterilant system
IN2012DE03088A (en)
PT2922554T (en) Terminally modified rna
GB201204183D0 (en) .
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
SG11201407089SA (en) Cyclosporine-containing, non-irritative nanoemulsion opthalmic composition
MX370649B (en) Process for the preparation of teneligliptin.
PT2708607T (en) Genetic markers for myb28
SG11201504433VA (en) Silicone-compatible photoinitiators
GB201423420D0 (en) Blackhoe loader
IN2015DN03815A (en)
GB201213032D0 (en) Continuous culture
GB201103407D0 (en) Genetic association
GB2491544A (en) Perpetum mobile
MX2012013246A (en) Dust supressant composition.
UA79072U (en) (4-tert-butylperoxy-4-methylpentyl)methacrylate
AU2013348363B2 (en) Terminally modified RNA
AU338012S (en) Dinosaur costume
AU348528S (en) A food mould
UA78206U (en) Technique for esophagogastroplasty with ileocecal segment
GB201222429D0 (en) Nolan
GB201201144D0 (en) Distributed versioning
IN2012DE01204A (en) "shikhar technology"
GB201300551D0 (en) Multi-part push-pulls